ReviewCurrent atherosclerosis reports2024
IL-6 and Cardiovascular Risk: A Narrative Review.
Review in Current atherosclerosis reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed.
- Efficacy of Xueshuantong Injection in Reducing Residual Inflammatory Risk in Unstable Angina Patients: A Randomized Double-Blind Controlled Trial.Chinese journal of integrative medicine · 2026Trial
- Associations of the inflammasome-dependent cytokine IL-18 with risk of coronary heart disease.Cardiovascular research · 2026Article
- Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure (SiN-HF).Cardiovascular drugs and therapy · 2026Article
- Selenium Attenuates LPS-Induced Injury in Ovine Granulosa Cells by Protecting Mitochondrial Ultrastructure and Cellular Homeostasis.Animals : an open access journal from MDPI · 2026Article
- Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies.Nature reviews. Cardiology · 2026Review
- The Immediate Impact of Infarct Size on the Systemic Inflammatory Response: IL-6 as Central Mediator Identified through Biomarker and Proteomic Profiling.Journal of cardiovascular translational research · 2026Article
- Effect of IL-6 inhibition on lipoprotein(a) levels: A systematic review and meta-analysis.American journal of preventive cardiology · 2026Review
- Review
- Systemic Inflammation and Malnutrition Define a High-Risk Phenotype in Chronic Limb-Threatening Ischemia.Journal of clinical medicine · 2026Article
- A high-fat diet with vitamin D and propylthiouracil produces a pro-atherogenic phenotype in rats.Animal models and experimental medicine · 2026Article
- Observational
- Review
- Admission C-Reactive Protein and Mortality After STEMI: A Retrospective Cohort Study Identifying Subgroup-Specific Risk Thresholds.Journal of clinical medicine · 2026Article
- Dose-dependent association between elevated resting IL-6 levels and severity of mental stress-induced myocardial perfusion defects.Psychological medicine · 2026Article
- Review
- The Mental Health-Acute Coronary Syndrome Continuum: Bidirectional Pathophysiological Links and Clinical Implications.Medical sciences (Basel, Switzerland) · 2026Review
- Exploring cardiovascular risk in subclinical hypothyroidism: The impact of TSHR gene expression and systemic biomarkers.Journal of cardiovascular and thoracic research · 2026Article
- Interleukin‑6 and ischemic stroke: From mechanisms to clinical prospects (Review).Molecular medicine reports · 2026Review
- Neutrophil Percentage-to-Albumin Ratio as a Novel Predictor of Diuretic Resistance and Mortality in Patients with Heart Failure with Preserved Ejection Fraction.Anatolian journal of cardiology · 2026Article
- Maladaptive Trained Immunity Drives Persistent IL-6 Production and Enhanced TLR Responsiveness in Monocyte-Derived Macrophages from People Living with HIV.Microorganisms · 2026Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe objective of this narrative review is to summarize data from recently published prospective observational studies that analyze the association between circulating interleukin-6 (IL-6) levels and cardiovascular clinical or imaging endpoints. RECENT
findingsHigher levels of IL-6 are associated with a higher risk of cardiovascular death, major adverse cardiovascular events, myocardial infarction, stroke, peripheral artery disease, and heart failure. Imaging studies have also shown an association between IL-6 and carotid intima-media thickness progression, carotid plaque progression, severity, and vulnerability. These observations have been consistent across a wide range of study populations and after adjusting for traditional and emerging risk factors including high-sensitivity C-reactive protein. Robust epidemiologic evidence supports IL-6 as a central mediator of cardiovascular risk along with human genetic studies and mechanistic experiments. Ongoing clinical studies are testing the therapeutic hypothesis of IL-6 inhibition in patients with atherosclerotic cardiovascular disease or heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.